Arthneeti

Galaxy Medicare Q2 FY27 Share Price & Earnings Call Analysis

₹18.00+0.00% today
Market cap
₹27 Cr
P/E
7.86
ROE
10.79%
PEG
0.13
Price to sales
0.69
Debt to equity
0.10
52W high / low
₹23.0 / ₹15.2
Sales growth (5Y)
6.84%
EBITDA margin
10.86%
Net profit margin
8.75%
Promoter holding
73.36%
Sales (last year)
₹40 Cr

Potential multibaggers · Q2 FY27

Potential multibaggers in Healthcare Equipment & Supplies
on management's own guidance

  1. Strong growth
    2
  2. Strong growth
    1
  3. Q-Line BiotechGood growth
    3
See all potential multibaggersWhere does Galaxy Medicare rank?

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Peers

Healthcare Equipment & Supplies companies ranked on guidance

#CompanyRevenue guidedMargin guidedMarket capP/E
140%+Flat₹627 Cr21.4
240%+Flat₹147 Cr16.8
3Q-Line Biotech20–40%Up 2%+₹1,467 Cr25.9
420–40%Flat₹18,144 Cr83.6
520–40%Flat₹173 Cr35.0
610–20%Up 2%+₹170 Cr18.8

Sign up free to see every company in the sector ranking and track Galaxy Medicare.

Pro shows every company guiding 40%+ revenue growth →Full Healthcare Equipment & Supplies ranking

Financials of Galaxy Medicare

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Shareholder Pattern

Galaxy Medicare

Shareholding breakup across reporting periods.

Sep 2025Mar 2026Sep 2026
Promoters +72.43%72.98%73.36%
DIIs +1.85%0.00%0.00%
Public +25.73%27.02%26.64%
No. of Shareholders856867821

Financials of Galaxy Medicare

Quarterly Results

Quarter-by-quarter operating performance

No quarterly results data available for this company yet.

Financials of Galaxy Medicare

Profit & Loss

Annual income statement trend

Mar 2021Mar 2023Mar 2024Mar 2025Mar 2026
Sales +28.5730.9435.8438.8639.77
Expenses +26.4128.5930.8734.1635.45
Operating Profit2.162.354.974.704.32
OPM %7.56%7.60%13.87%12.09%10.86%
Other Income +0.501.721.181.071.22
Interest0.800.950.940.740.28
Depreciation0.821.120.480.500.55
Profit before tax1.042.004.734.534.71
Tax %30.77%21.50%21.56%25.61%27.39%
Net Profit +0.721.573.713.373.42
EPS in Rs0.661.323.132.842.25
Dividend Payout %9.72%0.00%0.00%26.39%31.05%

Financials of Galaxy Medicare

Balance Sheet

Capital structure and asset base

Mar 2021Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital2.803.0411.8611.8615.17
Reserves12.8814.789.5112.2925.17
Borrowings +8.789.158.124.614.20
Other Liabilities +5.445.343.052.734.23
Total Liabilities29.9032.3132.5431.4948.77
Fixed Assets +13.9514.5714.4114.1315.03
CWIP0.200.060.000.000.00
Investments2.982.693.112.822.87
Other Assets +12.7714.9915.0214.5430.87
Total Assets29.9032.3132.5431.4948.77

Financials of Galaxy Medicare

Cash Flows

Operating, investing and financing cash movement

Mar 2021Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +5.563.652.714.491.77
Cash from Investing Activity +-4.46-1.91-0.650.32-13.90
Cash from Financing Activity +-1.11-1.80-2.08-4.7212.09
Net Cash Flow0.00-0.07-0.030.09-0.05
Free Cash Flow1.092.902.504.370.21
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit273%170%76%118%67%

Financials of Galaxy Medicare

Ratios

Working capital efficiency and return ratios

Mar 2021Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days93.26106.6574.6564.7269.93
Inventory Days73.90101.37123.7484.7598.62
Days Payable101.6691.7732.2922.0543.69
Cash Conversion Cycle65.50116.24166.10127.42124.86
Working Capital Days0.5136.1056.9368.9494.62
ROCE %18.53%17.72%13.86%

Continue your research

What Galaxy Medicare's management said in earlier quarters

Others in Healthcare Equipment & Supplies this season

  • Nureca Ltd (Q2 FY27)

    Year-on-year growth in revenue from operations: approximately 55% increase (585.99 vs 378.41 million standalone) . Key results statement takeaways from Nureca's

  • Aprameya Engineering Ltd (Q2 FY26)

    H1FY26 Revenue from Operations: Rs 421.4 Mn, up 343% YoY from Rs 92.7 Mn in H1FY25. Key investor presentation takeaways from Aprameya Engineering Ltd's Q2 FY26

  • Nureca Ltd (Q2 FY26)

    Q2 FY26 Revenue from Operations: INR 528 million, a 7% year-on-year (YoY) growth from INR 493 million in Q2 FY25. Key investor presentation takeaways from Nurec

  • QMS Medical Allied Services Ltd (Q3 FY26)

    Q3FY26 Revenue from Operations: ₹37.3 crore . Key investor presentation takeaways from QMS Medical Allied Services Ltd's Q3 FY26 investor presentation — and how

Compare:vs Poly Medicure Ltdvs Molbio Diagnostivs Sahajanand Medical Technologies Ltd